What's new — Ptsd¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 6 |
| last 2 months | 18 |
| last 3 months | 18 |
| last 6 months | 22 |
| last year | 30 |
| older than a year | 391 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-08 | Treatment of PTSD in the military health system: Which patients receive evidence based psychotherapy? — Psychiatry Res ([PMID 42906525](https://pubmed.ncbi.nlm.nih.gov/42906525/){target="_blank" rel="noopener"}) | military-and-veteran-populations |
| 2026-10-07 | Efficacy and safety of ketamine for post-traumatic stress disorder: A systematic review with narrative synthesis and consideration of military and veteran populations — PCN Rep ([PMID 42846850](https://pubmed.ncbi.nlm.nih.gov/42846850/){target="_blank" rel="noopener"}) | pharmacotherapy |
| 2026-10-05 | Benzodiazepine prescribing in chronic military-related PTSD: real-world patterns and correlates in specialized care — Front Psychiatry ([PMID 42898444](https://pubmed.ncbi.nlm.nih.gov/42898444/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-10-05 | Systematic review and meta-analysis: the effectiveness of cognitive behavioral therapy and eye movement desensitization and reprocessing in children and adolescents — Eur J Psychotraumatol ([PMID 42831259](https://pubmed.ncbi.nlm.nih.gov/42831259/){target="_blank" rel="noopener"}) | children-and-adolescents |
| 2026-10-02 | Examining the performance of the International Trauma Questionnaire with clinical checks in a multinational European sample — PLoS One ([PMID 42905693](https://pubmed.ncbi.nlm.nih.gov/42905693/){target="_blank" rel="noopener"}) | diagnosis-and-classification |
| 2026-10-02 | Complex post-traumatic stress disorder in refugees, asylum seekers, and internally displaced people: a systematic review and meta-analysis — Eur J Psychotraumatol ([PMID 42900526](https://pubmed.ncbi.nlm.nih.gov/42900526/){target="_blank" rel="noopener"}) | complex-ptsd |
| 2026-10-01 | Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review — JAMA Netw Open ([PMID 42900476](https://pubmed.ncbi.nlm.nih.gov/42900476/){target="_blank" rel="noopener"}) | mdma-and-psychedelic-assisted-therapy |
| 2026-10-01 | A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD — Neuropsychopharmacology ([PMID 42860436](https://pubmed.ncbi.nlm.nih.gov/42860436/){target="_blank" rel="noopener"}) | mdma-and-psychedelic-assisted-therapy |
| 2026-10-01 | Online stepped care for the treatment of posttraumatic stress disorder: A randomized controlled noninferiority trial — Behav Res Ther ([PMID 42832930](https://pubmed.ncbi.nlm.nih.gov/42832930/){target="_blank" rel="noopener"}) | dropout-and-nonresponse |
| 2026-10-01 | Multi-center, randomized controlled efficacy and comparative-effectiveness study evaluating ketamine, stellate ganglion blocks, combination treatment, and sham treatments for posttraumatic stress disorder and traumatic brain injury-associated headache: a study protocol — Pain Manag ([PMID 42817839](https://pubmed.ncbi.nlm.nih.gov/42817839/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-09-09 | Effectiveness and moderators of PE and CPT in adult PTSD treatment: a systematic review and meta-analysis — Eur J Psychotraumatol ([PMID 42712180](https://pubmed.ncbi.nlm.nih.gov/42712180/){target="_blank" rel="noopener"}) | comparative-psychotherapy-evidence |
| 2026-09-09 | MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis — Harv Rev Psychiatry ([PMID 42708350](https://pubmed.ncbi.nlm.nih.gov/42708350/){target="_blank" rel="noopener"}) | mdma-and-psychedelic-assisted-therapy |
| 2026-09-04 | Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder — J Trauma Stress ([PMID 42693902](https://pubmed.ncbi.nlm.nih.gov/42693902/){target="_blank" rel="noopener"}) | mdma-and-psychedelic-assisted-therapy |
| 2026-09-02 | Treatment discontinuation in a post-disaster outpatient clinic: A retrospective cohort study of post-traumatic stress disorder and complex post-traumatic stress disorder in Fukushima, Japan — PCN Rep ([PMID 42780894](https://pubmed.ncbi.nlm.nih.gov/42780894/){target="_blank" rel="noopener"}) | dropout-and-nonresponse |
| 2026-09-02 | Prolonged exposure in routine outpatient care: a naturalistic study of feasibility, safety and effectiveness — Eur J Psychotraumatol ([PMID 42766476](https://pubmed.ncbi.nlm.nih.gov/42766476/){target="_blank" rel="noopener"}) | dropout-and-nonresponse |
| 2026-09-01 | Psychosocial interventions for posttraumatic stress disorder in low- and middle-income countries: a Bayesian meta-analysis — Psychol Med ([PMID 42750363](https://pubmed.ncbi.nlm.nih.gov/42750363/){target="_blank" rel="noopener"}) | comparative-psychotherapy-evidence |
| 2026-09-01 | How common is alcohol use disorder in posttraumatic stress disorder? A systematic review, meta-analysis, and moderator analysis — Am J Addict ([PMID 42745626](https://pubmed.ncbi.nlm.nih.gov/42745626/){target="_blank" rel="noopener"}) | comorbidity |
| 2026-09-01 | Five-year outcomes in a randomised controlled trial of prolonged exposure therapy and supportive counselling for post-traumatic stress disorder in adolescents: a task-shifted intervention — Eur J Psychotraumatol ([PMID 42734593](https://pubmed.ncbi.nlm.nih.gov/42734593/){target="_blank" rel="noopener"}) | children-and-adolescents |
| 2026-07-03 | Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial — Commun Med (Lond) ([PMID 42533157](https://pubmed.ncbi.nlm.nih.gov/42533157/){target="_blank" rel="noopener"}) | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy |
| 2026-07-02 | Pacing in posttraumatic stress disorder therapy: A meta-regression of treatment frequency and completion rates — J Trauma Stress ([PMID 42504047](https://pubmed.ncbi.nlm.nih.gov/42504047/){target="_blank" rel="noopener"}) | dropout-and-nonresponse |
| 2026-07-01 | Are DSM-5 and ICD-11 posttraumatic stress disorder measures assessing the same construct? Evidence from a Rasch-based analysis — J Trauma Stress ([PMID 42438360](https://pubmed.ncbi.nlm.nih.gov/42438360/){target="_blank" rel="noopener"}) | diagnosis-and-classification |
| 2026-05-06 | State of the Science: The epidemiology of posttraumatic stress disorder — J Trauma Stress ([PMID 42089634](https://pubmed.ncbi.nlm.nih.gov/42089634/){target="_blank" rel="noopener"}) | epidemiology-and-risk, military-and-veteran-populations |
| 2026-05-02 | Pharmacotherapy for post traumatic stress disorder (PTSD) — Cochrane Database Syst Rev ([PMID 42206608](https://pubmed.ncbi.nlm.nih.gov/42206608/){target="_blank" rel="noopener"}) | pharmacotherapy |
| 2026-05-01 | Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial — JAMA Psychiatry ([PMID 41706459](https://pubmed.ncbi.nlm.nih.gov/41706459/){target="_blank" rel="noopener"}) | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy, pharmacotherapy |
| 2026-03-06 | Investigational drugs in PTSD — Neuropsychopharmacology ([PMID 41792251](https://pubmed.ncbi.nlm.nih.gov/41792251/){target="_blank" rel="noopener"}) | guidelines, pharmacotherapy |
| 2026-03-01 | Comparing dropout from cognitive processing therapy versus prolonged exposure: Results from a randomized clinical trial — J Consult Clin Psychol ([PMID 41926191](https://pubmed.ncbi.nlm.nih.gov/41926191/){target="_blank" rel="noopener"}) | clinical-trials-landscape, cognitive-processing-therapy, comparative-psychotherapy-evidence, dropout-and-nonresponse, guidelines, military-and-veteran-populations, patient-experience-and-advocacy, prolonged-exposure |
| 2026-03-01 | Guidance for simultaneous treatment of chronic pain and PTSD: a Delphi study — J Behav Med ([PMID 41851426](https://pubmed.ncbi.nlm.nih.gov/41851426/){target="_blank" rel="noopener"}) | comorbidity |
| 2026-03-01 | Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes — Eur Neuropsychopharmacol ([PMID 41825162](https://pubmed.ncbi.nlm.nih.gov/41825162/){target="_blank" rel="noopener"}) | mdma-and-psychedelic-assisted-therapy |
| 2026-03-01 | State of the Science: MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder — J Trauma Stress ([PMID 41820235](https://pubmed.ncbi.nlm.nih.gov/41820235/){target="_blank" rel="noopener"}) | mdma-and-psychedelic-assisted-therapy, red-flags-and-safety-concerns |
| 2025-12-01 | A double-blind, randomized, placebo-controlled trial of doxazosin for posttraumatic distressing dreams and sleep disturbance in men and women with posttraumatic stress — J Clin Sleep Med ([PMID 41042258](https://pubmed.ncbi.nlm.nih.gov/41042258/){target="_blank" rel="noopener"}) | sleep-and-nightmare-treatment |
Trials — what has moved¶
22 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 0 |
| trial records updated in the last month | 2 |
| trial records updated in the last 2 months | 5 |
| trial records updated in the last 3 months | 8 |
| trial records updated in the last 6 months | 9 |
| trial records updated in the last year | 15 |
Recently updated registrations¶
| Updated | Trial | Phase | Status | N | Cited on |
|---|---|---|---|---|---|
| 2026-10-23 | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Pa | PHASE2, PHASE3 | RECRUITING | 300 | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy |
| 2026-10-16 | Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder | PHASE2 | COMPLETED | 12 | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy |
| 2026-09-29 | A Transdiagnostic Sleep Health Intervention for Veterans With PTSD | NA | NOT_YET_RECRUITING | 182 | clinical-trials-landscape |
| 2026-09-23 | An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD | PHASE3 | RECRUITING | 300 | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy, pharmacotherapy |
| 2026-09-08 | Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Pa | PHASE2 | NOT_YET_RECRUITING | 76 | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy |
| 2026-08-14 | Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests | PHASE3 | ACTIVE_NOT_RECRUITING | 87 | clinical-trials-landscape, sleep-and-nightmare-treatment |
| 2026-08-13 | PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First | PHASE2 | ACTIVE_NOT_RECRUITING | 40 | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy |
| 2026-08-11 | Ketamine-enhanced Prolonged Exposure Therapy in PTSD | PHASE2 | COMPLETED | 73 | clinical-trials-landscape, pharmacotherapy |
| 2026-06-22 | A Study of Psilocybin for PTSD | PHASE1 | ACTIVE_NOT_RECRUITING | 20 | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy |
| 2026-05-01 | Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD | PHASE2 | RECRUITING | 175 | clinical-trials-landscape |
| 2026-04-29 | Nurse-Led PTSD Treatment in Primary Care | NA | RECRUITING | 100 | clinical-trials-landscape |
| 2026-04-15 | A Study to Assess the Use of Methylone in the Treatment of PTSD | PHASE1, PHASE2 | COMPLETED | 79 | clinical-trials-landscape, mdma-and-psychedelic-assisted-therapy, pharmacotherapy |
| 2026-01-28 | Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Diso | PHASE1, PHASE2 | COMPLETED | 4 | clinical-trials-landscape |
| 2026-01-15 | Evaluation of the PE Coach Mobile Application Among Veterans With PTSD | NA | RECRUITING | 124 | clinical-trials-landscape |
| 2025-12-08 | MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD | PHASE3 | COMPLETED | 16 | mdma-and-psychedelic-assisted-therapy |
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | Ketamine-enhanced Prolonged Exposure Therapy in PTSD | PHASE2 | 73 | Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | 2 | 67 | 0 |
| 2026-04-15 | A Study to Assess the Use of Methylone in the Treatment of PTSD | PHASE1, PHASE2 | 79 | Change From Baseline in CAPS-5 Total Severity Score | 1 | 67 | 0 |
| 2023-10-11 | A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MA | PHASE3 | 121 | Change From Baseline to Primary Endpoint in Clinician Administered PTS | 0 | 102 | 0 |
| 2022-02-18 | Implementing PTSD Treatment in FQHCs for Michigan Medicaid Enrollees | NA | 35 | Change in PTSD Symptoms (as Measured by the PCL-5) | 0 | 0 | 0 |
| 2021-09-16 | A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MA | PHASE3 | 100 | Change From Baseline to Primary Endpoint in Clinician Administered PTS | 2 | 90 | 0 |
| 2014-06-18 | Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD | PHASE3 | 304 | CAPS Recurrent Distressing Dreams Item | 35 | 281 | 0 |
10 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| military-and-veteran-populations | 2026-10-08 | 3 | 31 |
| pharmacotherapy | 2026-10-07 | 4 | 35 |
| children-and-adolescents | 2026-10-05 | 2 | 32 |
| red-flags-and-safety-concerns | 2026-10-05 | 2 | 32 |
| complex-ptsd | 2026-10-02 | 1 | 29 |
| diagnosis-and-classification | 2026-10-02 | 2 | 27 |
| clinical-trials-landscape | 2026-10-01 | 4 | 29 |
| dropout-and-nonresponse | 2026-10-01 | 5 | 35 |
| mdma-and-psychedelic-assisted-therapy | 2026-10-01 | 8 | 47 |
| comparative-psychotherapy-evidence | 2026-09-09 | 3 | 31 |
| comorbidity | 2026-09-01 | 2 | 33 |
| epidemiology-and-risk | 2026-05-06 | 1 | 33 |
| guidelines | 2026-03-06 | 2 | 33 |
| cognitive-processing-therapy | 2026-03-01 | 1 | 36 |
| patient-experience-and-advocacy | 2026-03-01 | 1 | 27 |
| prolonged-exposure | 2026-03-01 | 1 | 31 |
| sleep-and-nightmare-treatment | 2025-12-01 | 1 | 36 |
| neurobiology-and-mechanism | 2025-09-01 | 0 | 31 |
| emdr | 2025-07-05 | 0 | 27 |
| overview | 2025-02-01 | 0 | 28 |
| early-intervention-and-prevention | 2024-05-02 | 0 | 28 |
| moral-injury | 2024-02-01 | 0 | 27 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.